A growing number of prostate cancer experts argue that calling the lowest-risk prostate cancer "cancer" does more harm than ...

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

A cancer diagnosis is scary. Some doctors say it’s time to rename low-grade prostate cancer to eliminate the alarming C-word. Cancer cells develop in nearly all prostates as men age, and most prostate ...

Grade group 1 prostate cancer assessment should include PSA, stage, and disease volume for accurate risk evaluation. Active surveillance is safe for most low-risk patients, but higher-risk features ...

What we choose to call cancer may shape patients’ behavior in ways that influence their health outcomes. Relabeling low-grade prostate cancer as a precancerous condition, for instance, could reduce ...

Daniel W. Lin, MD, reviews new guidance on using MRI, biomarkers, and more, to improve the detection of prostate cancer.

A new study reveals that some men who are diagnosed with “Grade Group one” (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

Traditional approaches to prostate cancer screening involve blood tests, MRI, and biopsies. However, in addition to being uncomfortable, some of these procedures result in overdiagnosis of low-grade ...

The SPIRIT randomized trial provides level 1 data supporting short-term testosterone therapy to manage hypogonadal men with low grade, localized prostate cancer after radical prostatectomy.

Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding ...

Prostate cancer grading uses the Gleason score (6-10) and Grade Group (1-5) systems to estimate cancer aggressiveness based on how the cells look under a microscope. Higher numbers indicate ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...